Friday, December 6, 2024
12:00PM – 1:30PM ET
Please note this Clinical Conversation program is 12:00PM Eastern, 11:00AM Central, 10:00AM Mountain and 9:00AM Pacific.
PRESENTING FACULTY
 |
Richard Pratley, MD Associate Medical Director of Research and Education AdventHealth Diabetes Institute Orlando, FL |
 |
Antoinette Moran, MD Vice Chair of Faculty Development Marguerite & James Dugger Professor Pediatric Endocrinology University of Minnesota Minneapolis, MN |
PROGRAM DESCRIPTION
During this program, experts will present overviews of the importance of early screening and staging for type 1 diabetes (T1D), strategies and practical pearls for screening and follow-up, how to intervene early with disease-modifying therapies to delay progression to clinical T1D, as well as ongoing therapeutic advances in this setting. The program will be highly interactive, with case-based discussions, Q & A, and engaging animations to facilitate the uptake of key concepts in early T1D, and to allow for increased interaction with the expert faculty.
TARGET AUDIENCE
This activity is designed to meet the educational needs of Pediatric and Adult Endocrinologists, Pediatricians, Primary Care Providers, and Endocrine Nurses.
LEARNING OBJECTIVES
- Describe the clinical presentation of T1D in adults compared to children
- Identify appropriate autoantibody screening strategies for T1D, including type, frequency, and number
- Interpret results from screening protocols to drive management decisions
- Discuss the latest clinical evidence for efficacy and tolerability of newly approved and investigational immunomodulatory agents
- Implement strategies for appropriate clinical monitoring and early screening in individuals at highest risk
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this live virtual activity for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the virtually live activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 1.5 ANCC contact hours.
COMMISSION ON DIETETIC REGISTRATION (CDR) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 1.5 CPEU.
PHARMACISTS and PHARMACY TECHNICIANS (ACPE) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 1.5 knowledge-based CPE contact hours.
NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 45 days of your participation in the activity to meet the deadline for submission to CPE Monitor. Credits are generally reported during the first week of each month for those who claimed during the month prior.
INTERPROFESSIONAL CONTINUING EDUCATION (IPCE) CREDIT DESIGNATION
This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact: Med Learning Group at [email protected].
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at https://www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
